<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273713</url>
  </required_header>
  <id_info>
    <org_study_id>NL 49837.018.14</org_study_id>
    <nct_id>NCT02273713</nct_id>
  </id_info>
  <brief_title>The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)</brief_title>
  <acronym>ACTION</acronym>
  <official_title>The ACTION Trial: a Phase Ib/II Study on the Addition of Nab-paclitaxel (Abraxane) to Capecitabine and Oxaliplatin in the First-line Treatment of Metastasized Oesophagogastric Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oesophagogastric cancer is a major cause of cancer related mortality, with an overall 5-year&#xD;
      survival rate of 10% worldwide and patients are often diagnosed with locally advanced or&#xD;
      metastasized disease at first presentation. For advanced oesophagogastric cancer&#xD;
      fluoropyrimidines are the backbone of palliative chemotherapy and is commonly used in 2- or&#xD;
      3-drug combinations .&#xD;
&#xD;
      However, in clinical practice after progression on first line therapy, a substantial number&#xD;
      of oesophagogastric cancer patients may not be able to start second line chemotherapy due to&#xD;
      rapid clinical deterioration. Therefore, new triplets with high anti-tumor activity and low&#xD;
      toxicity are urgently needed.&#xD;
&#xD;
      Given the activity of capecitabine and oxaliplatin containing regimens and the potential of&#xD;
      taxanes in oesophagogastric cancer, the investigators propose a phase I study combining&#xD;
      capecitabine and oxaliplatin with Nab-paclitaxel.&#xD;
&#xD;
      Solvent-based taxanes (paclitaxel, docetaxel) can cause severe toxicities not only by the&#xD;
      active agents itself but also by the solvents like cremophor. Nab-paclitaxel (Abraxane) is a&#xD;
      solvent-free formulation of paclitaxel encapsulated in albumin. It does not require&#xD;
      premedication with corticosteroids or antihistamines to prevent the risk of solvent-mediated&#xD;
      hypersensitivity reactions. This new formulation improves safety profile, allows higher&#xD;
      dosing with shorter infusion duration, and produces higher tumor drug concentration. It has&#xD;
      proven activity in breast cancer, non small lung cancer and pancreatic cancer, as well as in&#xD;
      gastric cancer models.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1: To assess the safety and tolerability of Nab-paclitaxel added to oxaliplatin and&#xD;
      capecitabine at their currently optimal doses.&#xD;
&#xD;
      Phase 2: To determine the anti-tumor activity of Nab-paclitaxel when co-administered with&#xD;
      oxaliplatin and capecitabine in patients with irresectable or metastasized oesophagogastric&#xD;
      cancer in terms of progression free survival.&#xD;
&#xD;
      Study design This is a single-center, open label, dose finding, phase I/II study.&#xD;
&#xD;
      Intervention In the phase I part of the study, the dose of nab-paclitaxel in combination of&#xD;
      capecitabine and oxaliplatin will be escalated in fixed increments according to the dose&#xD;
      escalation scheme outlined below&#xD;
&#xD;
      Dose level Nab-paclitaxel Capecitabine Oxaliplatin Minimum Day 1 and 8 14 days Day 1 and 8&#xD;
      number of patients -1 40 mg/m2 1000 mg/m2 65 mg/m2 -&#xD;
&#xD;
        1. (starting) 60 mg/m2 1000 mg/m2 65 mg/m2 3&#xD;
&#xD;
        2. 80 mg/ m2 1000 mg/m2 65 mg/m2 3&#xD;
&#xD;
        3. 100 mg/ m2 1000 mg/m2 65 mg/m2 3&#xD;
&#xD;
        4. 120 mg/ m2 1000 mg/m2 65 mg/m2 3&#xD;
&#xD;
      In the phase II part of the study the maximum tolerated dose from the phase I part of the&#xD;
      study will be used in combination with fixed dosages of capecitabine and oxaliplatin;&#xD;
      nab-paclitaxel day 1 and 8 according to the Maximum Tolerated Dose (MTD) of the phase 1 part&#xD;
      of the study combined with capecitabine for 14 days at 1000mg/m2 twice daily and oxaliplatin&#xD;
      day 1 and 8 65mg/m2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>12 months</time_frame>
    <description>Identifying the Maximum Tolerated Dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free survival</measure>
    <time_frame>approximately 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>approximately 36 months</time_frame>
    <description>Adverse event, serious adverse events according to NCI CTC version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>approximately 36 months</time_frame>
    <description>Response rate according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>approximately 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurotoxicity</measure>
    <time_frame>approximately 36 months</time_frame>
    <description>Self reported neurotoxicity according to EORTC QLQ CIPN20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>approximately 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Toxicity</condition>
  <arm_group>
    <arm_group_label>Nab-Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-Paclitaxel added to first line treatment with Oxaliplatin and Capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Nab-paclitaxel added to first line treatment oxaliplatin and capecitabine</description>
    <arm_group_label>Nab-Paclitaxel</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must provide written informed consent according to ICH/GCP, and&#xD;
             national/local regulations prior to any screening procedures.&#xD;
&#xD;
          -  Patients with histologically confirmed diagnosis of metastatic or irresectable&#xD;
             carcinoma of the stomach or oesophagus&#xD;
&#xD;
          -  Patients with metastatic or irresectable carcinoma of the stomach or oesophagus not&#xD;
             pre-treated with chemotherapy or radiotherapy for irresectable or metastatic disease.&#xD;
&#xD;
          -  Measurable disease as assessed by RECIST 1.1&#xD;
&#xD;
          -  ECOG (WHO) performance status 0-2&#xD;
&#xD;
          -  Patient has adequate bone marrow and organ function&#xD;
&#xD;
          -  If a female patient is of child-bearing potential: negative serum pregnancy test, If&#xD;
             sexually active, the patient must agree to use contraception.&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic treatment for metastatic or irresectable stomach or oesophageal cancer.&#xD;
&#xD;
          -  Evidence of disease progression within 3 months after completion of adjuvant or&#xD;
             neoadjuvant treatment containing capecitabine and/or oxaliplatin.&#xD;
&#xD;
          -  History of hypersensitivity to nab-paclitaxel, capecitabine or oxaliplatin.&#xD;
&#xD;
          -  All target lesions in a radiation field without documented disease progression.&#xD;
&#xD;
          -  WHO 2-4&#xD;
&#xD;
          -  Use of other investigational drugs within 30 days of enrollment.&#xD;
&#xD;
          -  Patient has known brain metastases, unless previously treated and well-controlled for&#xD;
             at least 3 months (defined as clinically stable, no oedema, no steroids and stable in&#xD;
             2 scans at least 4 weeks apart).&#xD;
&#xD;
          -  History of malignancy in the last 5 years. Patients with prior history of in situ&#xD;
             cancer or basal or squamous cell skin cancer are eligible. Patients with other&#xD;
             malignancies are eligible if they were cured by surgery alone or surgery plus&#xD;
             radiotherapy and have been continuously disease-free for at least 5 years.&#xD;
&#xD;
          -  Patients who are not willing to avoid consumption of Seville oranges, grapefruit or&#xD;
             grapefruit juice grapefruit hybrids, pomelos and exotic citrus fruits during the&#xD;
             entire study.&#xD;
&#xD;
          -  Patient is currently being treated with drugs known to be strong inhibitors or&#xD;
             inducers of CYP3A4 or CYP2C8, which cannot be discontinued or switched to a different&#xD;
             medication 7 days prior to starting study treatment and for the duration of the study.&#xD;
&#xD;
          -  Patient has active, uncontrolled bacterial, viral or fungal infection(s) requiring&#xD;
             systemic therapy.&#xD;
&#xD;
          -  Patient has known historical or active infection with human immunodeficiency virus&#xD;
             (HIV), hepatitis B or hepatitis C.&#xD;
&#xD;
          -  Patient has any other concurrent severe and/or uncontrolled medical condition that&#xD;
             would, in the investigator's judgment contraindicate patient participation in the&#xD;
             clinical study (e.g. hematological, cardiovascular, lung disease etc)&#xD;
&#xD;
          -  Patient is enrolled in any other clinical protocol or investigational trial with the&#xD;
             same primary endpoint.&#xD;
&#xD;
          -  Patients who in the investigators' opinion may be unwilling, unable or unlikely to&#xD;
             comply with requirements of the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanneke WM van Laarhoven, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center, Medical Oncology</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>H.W.M. van Laarhoven</investigator_full_name>
    <investigator_title>Prof. dr.</investigator_title>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>Metastasized</keyword>
  <keyword>Nab-paclitaxel</keyword>
  <keyword>Toxicity</keyword>
  <keyword>First line treatment</keyword>
  <keyword>Phase Ib/II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

